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Summary
Introduction
Though less commonly observed compared to the other organs, 
ocular ndings may occur in patients with leukemia.1 Since the 
initial description of leukemic retinopathy in the 1860s, it has been 
shown that nearly all eye structures may be affected in leukemia 
patients.2 Since the mean life expectancy of leukemic patients is 
increasing due to the advances in diagnosis and treatment, the 
incidence of ocular ndings is increasing. Ophthalmic signs in 
leukemia can be observed at the onset of disease or during follow-
up. According to the literature, ocular involvement occurs in 9% to 
90% of leukemia patients and most frequently affects the retina;3,4 
however, the relationship between the prognosis of leukemia and 
ocular manifestations remains unclear. In the present study, we 
aimed to investigate ophthalmic manifestations in patients with 
acute leukemia and to determine whether there is a relationship 
between these manifestations and morbidity or prognosis.
Materials and Methods 
The study included 120 children with acute leukemia who 
were treated in our department between 1995 and 2010. Patient 
age, gender, hematologic parameters at diagnosis, organomegaly, 
and extramedullary involvement was recorded. 
Acute leukemias were classi ed according to the French-
American-British (FAB) classi ion as follows: acute 
lymphoblastic leukemia (ALL), acute myeloblastic leukemia 
(AML), and acute mixed leukemia. For morphological 
, a bone marrow aspirate was stained with 
Wright stain, then examined with an optical microscope. 
Immunophenotyping was performed via 
(Becton Dickons Canto II, Sysmex XT-2000i®). Conventional 
cytogenetic analysis was performed in all patients. Since 2003, 
uorescence in situ hybridization analysis for speci  areas of 
chromosomes was performed, as well as chromosomal analysis. 
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Patients diagnosed with ALL between 1995 and 2005 were 
given the St. Jude Total XIII protocol, those diagnosed with 
ALL between 2005 and 2006 were given the ALL-Berlin-
Frankfurt-Munster-1990 (ALL-BFM 90) protocol, and those 
diagnosed with ALL between 2006 and 2010 received the ALL-
BFM 95 protocol. Patients diagnosed with AML received the 
AML-Berlin-Frankfurt-Munster-1993 (AML-BFM 93) protocol 
between 1995 and 2007, and after 2007 they received the AML-
BFM 2004 protocol. 
Findings at admission (FAA) were defined as the ocular 
manifestation(s) observed at the time of leukemia diagnosis, 
whereas findings during follow-up (FDF) were defined as 
ocular manifestations observed during or after the treatment 
of leukemia. At first admission with the diagnosis of acute 
leukemia, the patients underwent a detailed ophthalmologic 
examination by an ophthalmologist. All the patients who 
were followed in our department were also examined at 
remission and at the end of treatment. Ophthalmologic 
examinations were repeated in cases of relapse or any 
complaints concerning the eyes. Ocular manifestations at 
the time of leukemia diagnosis and during the course of 
follow-up were recorded. Visual acuity measurement and 
biomicroscopic examination including direct and indirect 
ophthalmoscopy were performed in all patients at diagnosis 
and during follow-up. Fundus photographs were obtained 
from selected patients as needed. 
Statistical Methods
Statistical evaluation of the data was performed using 
Statistical Package for the Social Sciences v.19.0 for Windows. 
Benchmark analysis of categorical data was performed using 
chi-square and Fisher’s exact tests, Kruskal-Wallis ANOVA 
analysis of quantitative data and Mann-Whitney U test were 
used. Arithmetic mean ± standard deviation and median values 
were used for quantitative data and frequency and percentage 
were used for qualitative data as descriptive statistics. The level 
of statistical significance was set at α=0.05.
The present study was performed in accordance with the 
ethical standards set forth in the 1964 version of the Declaration 
of Helsinki, and the Başkent University Ethics Committee 
approved the study protocol. 
Results
In total, 83 (69.2%) patients had ALL, 35 (29.1%) had 
AML, and 2 (1.7%) had acute mixed leukemia. Table 1 shows 
the patients’ demographic data. The distribution of gender, 
leukemic cell morphology, and immune-phenotype did not 
differ between the patients with ALL and AML. Considering 
complete blood count data at diagnosis, only the platelet counts 
were different, being lower in AML patients compared to 
those in patients with ALL (p=0.002). In all, 30% of the AML 
patients and 33% of ALL patients admitted with a leukocyte 
count >20x109/L. However, there was no correlation between 
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Table 1. Demographic and organ involvement data of patients with leukemia
ALL AML Total
Number of patients (%) 83 (69.2) 35 (29.1) 120
Male/Female 55/28 22/13 79/41
Age at the diagnosis 5.5±3.5 9.0±5.5 6.6±4.5
Extramedullary involvement at diagnosis Kidney 10 2 12 (31%)
Central neurvous system 7 2 9 (23%)
Gastrointestinal system 1 5 6 (15%)
Eye 2 3 5 (13%)
Bone 2 0 2 (5%)
Others* 3 2 5 (13%)
Total 25 14 39 (13%)
Sites of ophthalmologic manifestations** Retina 1/9 1/5 16
Conjunctiva 1/9 -/5 15
Optic disk 1/6 -/2 9
Cranial nerve 1/5 1/- 7
Orbita 1/1 3/1 6
Choroid 1/- 1/- 2
Cornea -/2 -/- 2
Lens -/1 -/- 1
Total 6/33 6/13 58
*Pleura, pericardium, and thymus
**Numbers in the first two columns represent number of “primary/secondary” manifestations 
ALL: Acute lymphoblastic leukemia, AML: Acute myeloblastic leukemia
Turk J Ophthalmol 46; 2: 2016
64
the high leukocyte counts and ophthalmologic manifestations 
in our patients. 
Extramedullary Involvement
In total, 39 (32.5%) of the patients had extramedullary 
involvement at the time of diagnosis; 64% (n=25) of cases 
were observed in ALL patients, versus 36% (n=14) in AML 
patients (Table 1). The most frequently involved extramedullary 
organ was the kidney [n=12 (31%)], followed by the central 
nervous system (CNS) [n=9 (23%)], gastrointestinal system 
[n=6 (15.4%)], eye [n=5 (13%)], bone [n=2 (5.1%)], pleura 
[n=2 (5%)], pericardium [n=2 (5%)] and thymus [n=1 (2.5%)]. 
Eye and gastrointestinal involvement were more common in the 
AML patients than in the ALL patients, but the difference was 
not significant (p=0.053) (Table 1). Relapse occurred in 20 of 
the patients with acute leukemia. Only one of the patients with 
acute mixed-lineage leukemia had orbital relapse together with 
CNS involvement 10 months after diagnosis. He was given a 
protocol for the treatment of children with relapsed ALL (ALL 
REZ-BFM relapse protocol) and cranio-spinal radiotherapy was 
administered. The last eye examination was normal. The patient 
later died due to sepsis. 
Ophthalmologic Manifestations and Anatomic Distribution
Ophthalmologic manifestations occurred in 41 (34.2%) 
of the patients (17 male and 24 female) with acute leukemia. 
Among these, 32 had manifestations at the time of diagnosis 
(FAA), whereas 9 of them developed secondary ophthalmic 
manifestations after the diagnosis (FDF) (mean 9 months). There 
were no significant differences in ophthalmic manifestations 
according to the patients’ leukemia morphology or immune-
phenotype. Since some patients had multiple ophthalmic 
manifestations, 58 ophthalmic manifestations in total were 
observed in 41 patients. In our study, survival and relapse 
rates were similar in children who had ophthalmological 
manifestations at admission compared to those without 
ophthalmological findings.
Mean age at diagnosis of leukemia was higher in the patients 
with ophthalmologic manifestations (for ALL 6.4, AML 10.9, 
total 7.9 years) than those without ophthalmologic involvement 
(for ALL 5.2, AML 7.6, total 5.9 years). This difference was 
significant in patients with AML (n=35, p=0,006) and it was 
consistent when we analyzed all the patients with leukemia 
(n=120, p=0.04). Although the mean age at diagnosis was 
also higher in ALL patients with ophthalmologic findings, the 
difference was not significant (n=83, p=0.375).
In all, ophthalmic manifestations observed in our patients 
were mostly FDF [46 FDF manifestations (79%) vs 12 FAA 
manifestations (21%)]. The retina was the most common site 
of involvement. In total, there were 16 retinal manifestations 
(2 FAA and 14 FDF). Retinal manifestations did not differ 
significantly according to the hematological parameters. 
Among patients with retinal involvement at admission, 
an 18-month-old male diagnosed with B-cell ALL and 
significant leukocytosis (400x109/L) at the time of diagnosis 
showed extended leukemic mass below the retina and 
retinal detachment (Figure 1). Following leukapheresis and 
systemic chemotherapy, the mass disappeared. Unfortunately, 
approximately 1 year after diagnosis, the patient had bone 
marrow relapse without ocular involvement. He underwent 
bone marrow transplantation, but had another relapse after 
transplantation and passed away. The other patient with retinal 
involvement at admission was a 14-year-old female diagnosed 
with secondary AML-M5 who had completed chemotherapy 
for osteosarcoma 2 years earlier. At the initial examination, 
the patient had blurred vision and serous retinal detachment. 
An orbital tumor was also observed via cranial magnetic 
resonance imaging. Cytogenetic analysis of the bone marrow 
was normal. Following treatment, her ocular symptoms 
improved; however, during the third month of treatment she 
died due to sepsis. Another patient with retinal detachment 
at diagnosis was a 15-year-old male with AML-M2 blast cell 
morphology and t(8;21) translocation. His hemoglobin level 
was 5.1 g/dl; leukocyte and thrombocyte counts were 6,100/
mm3 and 7,000/mm3 respectively. In addition to the retinal 
detachment, intraretinal hemorrhage and orbital granulocytic 
sarcoma were observed at time of diagnosis. The patient was 
treated with AML BFM 93 protocol and short-term high dose 
methylprednisolone. His ocular findings completely resolved 
after the methylprednisolone treatment.5
Figure 1. The retinal hemorrhages of patients with acute leukemia (A, right eye; 
B, left eye)
Figure 2. Retinal detachment in a patient with acute leukemia
Figure 3. Retinal scar in a patient with acute myeloblastic leukemia (A, right 
eye; B, left eye)
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Retinal pathologies during follow-up included retinal 
hemorrhage (n=10; 8 in ALL and 2 in AML patients), retinal 
detachment (n=2; 1 ALL and 1 AML), and retinitis (n=2; 
both AML) in our patients (Figure 2). Retinitis was noted in 2 
patients with AML. One of them was diagnosed with FAB AML-
M5 at the age of 7 months. During maintenance of AML-BFM 
treatment, he developed cytomegalovirus (CMV) retinitis treated 
with intravenous ganciclovir, then with oral valganciclovir for 1 
year. This patient healed with a retinal scar and as of the time 
this manuscript was prepared had been in remission for 3 years 
(Figure 3). 
Conjunctival manifestations were observed in 15 patients 
(10 ALL and 5 AML). Conjunctival involvement at admission 
was observed in only 1 patient, a 12-year-old female with pre-B-
cell ALL. Leukemic infiltration was present in the right auricle 
along with both conjunctivas. Leukemic infiltration was noted 
in samples obtained from the ear, but conjunctival samples 
could not be obtained. The patient started chemotherapy; 
her ophthalmologic evaluation was normal after two weeks of 
treatment. She has been in remission for the last 7 years. In 
all, 14 patients had conjunctival manifestations during follow-
up, of which 9 (6 ALL and 3 AML) had conjunctivitis. In 8 of 
these patients, conjunctivitis was infectious in origin and in the 
other it was allergic. In 2 of the 5 patients with conjunctival 
hemorrhage the platelet count was <20x109/L at the time of 
hemorrhage. Trauma was suspected in these cases.
Optic disc manifestations were observed in 9 patients (1 
FAA and 8 FDF). The patient with involvement at admission 
had Philadelphia chromosome positive T-cell ALL. He had 
papilledema with optic nerve and CNS involvement at the time 
of diagnosis (Figure 4). The Non-Hodgkin Lymphoma-Berlin-
Frankfurt-Munster-1990 (NHL-BFM 90) treatment protocol 
was initiated, along with cranial radiation therapy. Ophthalmic 
examination was normal 3 months after the initiation of ALL 
treatment. He has been in remission for the last 4 years.
Cranial nerve manifestations were noted in 7 patients (2 
FAA and 5 FDF). Both patients with primary involvement had 
Horner’s syndrome at the time diagnosis; one of the patients was 
an 8-year-old male with AML-M4 with inversion of chromosome 
16. After treatment, he has been well for the last 10 years 
without any ocular problems. The other patient was a 3-year-old 
male with B-cell ALL. This patient has been in remission for the 
last 5 years and his ophthalmic examination was normal at the 
last visit.
Orbital manifestations were recorded in 6 patients (4 FAA 
and 2 FDF). All orbital involvements at admission diagnosed 
with orbital granulocytic sarcoma were patients with AML 
(Figure 5). Three of them also had retinal involvement. All 
granulocytic sarcomas disappeared within 10 days of AML 
treatment. 
In total, 2 patients, one with ALL-L1 and the other with 
AML-M5 had choroidal manifestations; both had involvement 
at admission and serous retinal detachment due to choroidal 
infiltration. They both returned to normal with leukemia 
treatment. 
Two patients with ALL developed corneal pathology during 
follow-up that was related to toxicity of chemotherapeutics. 
One patient had evidence of subcapsular cataract as a secondary 
manifestation, which was also related to chemotherapy.
During bone marrow relapse, 5 patients had ocular manifestations; 
retinal manifestations during follow-up were observed in 3 of them 
(2 intraretinal hemorrhage and 1 retinitis) and cranial nerve findings 
were noted during follow-up in 2 patients. 
Discussion
As the life expectancy of children with leukemia has 
increased due to advances in diagnosis and treatment methods, 
observation of the complications associated with leukemia 
has also increased. The limited studies on ophthalmologic 
signs in acute leukemia showed that the use of modern 
treatments has caused an increase in secondary ophthalmologic 
manifestations.6 Ophthalmologic manifestations in pediatric 
leukemia patients may occur either directly due to leukemia 
or as a result of problems that occur during the course of 
disease. Although our study was retrospective in design, the 
ophthalmologic manifestations of all patients, both at the time 
of diagnosis and as needed during the course of illness, were 
observed and followed by experienced ophthalmologists at 
the same center; therefore, we think this study is comparable 
in nature to a prospective study. Although age and gender 
distribution in the study population was normal, the 
percentage of patients with AML (approximately 30%) was 
higher than in previously reported (15-20%) studies,7 which 
might have been because patients referred to our hospital were 
mostly children with AML.
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Figure 4. Optic disc signs in patients with acute leukemia. A. Papillary edema at 
optic disc. B. Atrophy at optic disc
Figure 5. Orbital magnetic resonance images of patient with orbital granulocytic 
sarcoma before (a) and after (b) treatment
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Russo et al.8 studied ophthalmologic manifestations in 
180 children with acute leukemia and observed that ocular 
manifestations occurred with a higher frequency in AML patients 
than in those with ALL. In addition, bone marrow relapse 
developed more frequently in the patients with specific ocular 
manifestations than in the patients with non-specific eye lesions 
or non-ophthalmologic manifestations. Furthermore, CNS and 
bone marrow relapse occurred more frequently in the patients 
with specific ocular lesions, resulting in a decrease in mean 
duration of survival. In the present study ocular involvement 
occurred more frequently in patients with AML compared to 
those with ALL, but the difference was not significant (p=0.053). 
There was no correlation between ophthalmologic manifestations 
and the frequency of relapse, morphologic or immunophenotype, 
or gender distribution in the present study. Our study includes a 
considerable number of patients with acute leukemia; however, 
inconsistent results compared to the study mentioned above 
indicates the need for larger/multi-centric studies.
Many studies have examined the effect of age on prognosis 
in acute leukemia.9 In the present study, the occurrence of 
ophthalmologic manifestations increased with age in children 
with leukemia. Age is a strong prognostic factor in ALL, 
therefore our finding that the ALL patients with ophthalmologic 
findings were older than those without ophthalmologic findings 
supports this notion. However, in AML the age is not a strong 
prognostic factor.7 Our study suggests that children with AML, 
especially those in the older age group, should be considered for 
ophthalmologic findings. Nevertheless, this finding should also 
be confirmed with further studies.  
With the advent of modern treatment regimens, some 
prognostic factors that were once important are becoming less 
significant. As such, identification of novel risk factors that can 
be used to inform patient treatment and follow-up are needed. 
In 1976 Ridgway et al.10 reported that among 657 children 
admitted with acute leukemia, 9% had ocular signs, the most 
common of which was retinal hemorrhage. In addition, 29 
patients with leukemic involvement in the eyes mostly had 
bone marrow relapse, of which 27 patients had meningeal 
involvement based on evaluation of cerebrospinal fluid. None 
of these patients were treated with CNS prophylaxis, because 
the chemotherapy protocols did not include CNS prophylaxis 
at that time. In the present study 7 (17%) patients had CNS 
involvement with ocular manifestations (3 optic disc, 2 orbital, 
and 2 cranial nerve involvement) at the time of diagnosis. Only 
1 patient who had CNS relapse also had orbital relapse. These 
findings suggest that including CNS prophylaxis in leukemia 
protocols prevents ocular involvement; however, larger scale 
studies are needed to confirm this conclusion. 
In a recent report, Curto et al.11 revealed that 32 of 38 
patients with leukemic ocular involvement remitted, but that 6 
of those patients had ocular relapse; therefore, more aggressive 
treatment was suggested in patients with ocular involvement, 
which could improve not only survival, but visual function as 
well. According to the literature, CNS and bone marrow relapse 
are more common in ALL patients with ocular signs, and result 
in a decrease in the duration of survival.6,12 Therefore, the 
presence of ophthalmologic manifestations was thought to be a 
marker of poor prognosis. However, the present study’s findings 
do not support this notion. In the present study there was no 
difference in survival between the ALL patients with and without 
ocular signs, and survival and relapse rates were similar overall in 
children who had ophthalmological manifestations at admission 
compared to those without ophthalmological findings.
Several reports indicated that the most common ocular 
signs were retinal findings, of which the most common was 
retinal hemorrhage.12,13,14,15 Lower platelet counts and higher 
leukocyte counts were found in the acute leukemia patients with 
intraretinal hemorrhage. The researchers suggested that ocular 
signs in acute leukemia might be associated with the leukocyte 
and platelet counts. In the present study retinal involvement was 
the most common ophthalmic manifestation, consistent with 
these reports. However, we found no correlation between either 
retinal manifestations at admission or during follow-up and 
hematologic parameters, especially the leukocyte and platelet 
counts. Similarly, Ergur et al.16 studied 42 children with acute 
leukemia and reported that 24 had ocular manifestations, but 
that ophthalmic manifestations and hematological parameters 
were not correlated. 
Conclusion
In the present study, ophthalmic manifestations at admission 
or during follow-up differed according to gender and type of 
leukemia, and increased in frequency with age at admission. 
Ophthalmic manifestations were observed more frequently in the 
patients with AML than in those with ALL, but the difference 
was not significant. Despite various recommendations regarding 
the treatment of patients with primary ocular involvement, 
definitive information is still lacking. As this study did not 
directly demonstrate that ophthalmic manifestations negatively 
affect prognosis, alterations to current treatment protocols are 
not recommended. Multi-centric studies with larger patient 
groups are needed to further elucidate this issue.
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